This is one of the reasons I believe so strongly in coaching and accountability alongside a GLP-1.
In a 2026 observational study of 7,642 adults with type 2 diabetes starting semaglutide or tirzepatide, those who were fully engaged with remote coaching, regular weight tracking, and the digital program were much more likely to reach meaningful weight-loss milestones.
At 12 months, 60.1% of fully engaged participants had lost at least 10% of their body weight, compared with 29.0% of those who were not engaged. More than half of the engaged group also reached at least 15% weight loss, compared with about one in five of the non-engaged group. Diabetes Journals
That does not prove coaching caused the difference. People who engage more may differ in motivation and other ways. But it does reinforce something I see every week: support, accountability, tracking, and follow-through matter.
A separate real-world study of 57,975 people using semaglutide or tirzepatide, those who actively engaged with coaching, regular weight tracking, and a digital support program lost an average of about 11.5% of their body weight at 5 months, compared with about 8% among those who were not engaged. PubMed Central (PMC)
Another large study of more than 100,000 GLP-1/GIP users found that highly engaged participants lost about 21.5% at 11 months versus 17.0% among those who were not maximally engaged. Engagement included coaching, weight tracking, and use of the program. PubMed Central (PMC)
That doesn’t mean coaching magically causes the difference. These are observational studies, and people who engage may differ in other ways too.
But it does reinforce something I see in coaching all the time:
Accountability helps turn information into action.
Knowing you should move more is different from actually finding a way to move consistently.
Knowing protein matters is different from figuring out what works when your appetite changes.
Knowing strength matters is different from building a routine you can actually sustain.
And then there is the question nobody wants to think about too early:
What happens later?
In the STEP 1 extension, people who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost within the following year. PubMed Central (PMC)
In SURMOUNT-4, people who stopped tirzepatide after the initial treatment period regained an average of about 14% of their body weight over the next year, while those who continued treatment maintained and added to their weight loss. JAMA Network
That is not a failure of willpower.
Obesity is complex, and for many people medication may remain part of long-term treatment.
But it makes me even more interested in this question:
While the medication is giving you this opportunity, what are you learning that you can keep?
How to nourish yourself.
How to strength train.
How to recognize your patterns.
How to navigate restaurants, travel, stress, and weekends.
How to understand your body beyond the scale.
How to reset without punishment.
How to make decisions with more confidence.
This is where I think accountability becomes so valuable.
When I coach someone, I sometimes describe it like riding a bike with training wheels. I’m there to support, guide, encourage, and help them learn what works.
But I don’t want those training wheels on forever.
I want you building enough knowledge, skills, and confidence that you become stronger at navigating your own health.
The prescription starts the journey. Lifestyle creates the transformation.

